Jasper Therapeutics enters its May 19 earnings report with two analyst downgrades landing the same morning, a stock trading near the floor of its recent range, and a clinical setback still casting a shadow over the lead program.
The analyst community turned sharply more cautious Friday. TD Cowen dropped its rating from Buy to Hold — no longer willing to argue for upside — just hours before the print. RBC Capital maintained its Sector Perform but trimmed its target from $4 to $3, a further compression on a name already trading at $0.85. The broader trend from the recent analyst changes has been relentlessly downward: targets have been cut at Evercore ISI, RBC, and others over the past several months, leaving the consensus split between two buys and four holds. Importantly, the UBS target of $1.50 — set in March — and Evercore's $7 target (also cut dramatically from $12) are still well above current prices, but that gap increasingly reflects analyst hesitation to abandon coverage rather than genuine conviction.
The bear case centers on a faulty drug lot investigation that forced a pause in the ETESIAN asthma trial for briquilimab. That setback prompted a capital raise of $30 million through common stock and warrants, diluting existing holders and resetting the share count that underpins analyst models. Bulls hold onto the clinical efficacy data — an 89% complete response rate in hematopoietic stem cell conditioning — and argue that briquilimab's shorter half-life versus competitors is a genuine differentiator. That debate has not been resolved by the data released to date.
The stock's recent history of post-earnings moves provides little comfort. The March 30 print triggered a one-day fall of nearly 17%, followed by a further 35% loss over the following five days. The most recent event on May 14 — a separate announcement — brought an additional 8% drop in a single session. The shares are down 11% in the past day alone and have lost about 9% over the past month, now trading near $0.85 against a micro-cap market cap of roughly $27 million. Short interest, while elevated at around 8.9% of the free float, has actually eased 32% over the past month — a sign that some short sellers have covered rather than pressed the thesis. Borrow availability is ample at 263% of short interest, with a cost to borrow near 3%, suggesting no squeeze dynamic is building. Options positioning, meanwhile, remains relatively mild — the put/call ratio is 0.40, just above its 20-day average and well short of the 52-week high of 0.43 — implying the options market is not aggressively positioning for a sharp move in either direction.
The earnings print is therefore less a valuation test and more a clinical credibility test: whether management can provide a clear timeline for resolving the briquilimab investigation and resuming the ETESIAN trial in a way that restores confidence in the development roadmap.
See the live data behind this article on ORTEX.
Open JSPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
